Melanosomal proteins as melanoma-specific immune targets

Melanoma Research

Volumn 7, Issue 2, 1997, Pages 83-95

  Sakai, C ^a   Kawakami, Y ^b   Law, L W ^b   Furumura, M ^a   Hearing Jr , V J ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

cytotoxic T lymphocytes; gp 100; MART1; TRP; tyrosinase

Indexed keywords

CELL PROTEIN; DOPACHROME; DOPACHROME TAUTOMERASE; GLYCOPROTEIN; INTERLEUKIN 2; MELANIN; MELANOMA VACCINE; MEMBRANE PROTEIN; MONOPHENOL MONOOXYGENASE; OXIDOREDUCTASE; PEPTIDE DERIVATIVE; TUMOR VACCINE;

ACTIVE IMMUNIZATION; ADOPTIVE TRANSFER; AUTOIMMUNITY; CELL TRANSFORMATION; CELLULAR IMMUNITY; GENE LOCUS; HUMAN; HUMORAL IMMUNITY; IMMUNOTHERAPY; MELANOCYTE; MELANOMA; MELANOSOME; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN PIGMENTATION; T LYMPHOCYTE; TARGET CELL;

EID: 0030949515     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199704000-00001     Document Type: Review

References (130)

1. Kawamura K, Fitzpatrick TB, Seiji M. Biology of Normal and Abnormal Melanocytes. Baltimore: University Park Press, 1971; 1-411.
2. Montagna W, Parakkal PF. The Structure and Function of Skin. New York: Academic Press, 1974; 1-433.
3. Hearing VJ, King RA. Determinants of skin color: melanocytes and melanization. In: Levine N, ed. Pigmentation and Pigmentary Abnormalities. New York: CRC Press, 1993: 3-32.
4. Cascinelli N, Marchesini R. Increasing incidence of cutaneous melanoma, ultraviolet radiation and the clinician. Photochem Photobiol 1989; 50: 497-505.
5. Setlow RB, Grist E, Thompson K, Woodhead AD. Wave-lengths effective in induction of malignant melanoma. Proc Natl Acad Sci USA 1993; 90: 6666-6670.
6. Wolf P, Donawho CK, Kripke ML. Effect of sunscreens on UV radiation-induced enhancement of melanoma growth in mice. J Natl Cancer Inst 1994; 86: 99-105.
7. Prota G. Melanins and Melanogenesis. New York: Academic Press, 1992; 1-290.
8. King RA, Oetting WS, Hearing VJ. Albinism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease, New York: McGraw-Hill, 1995; 4353-4392.
9. Hearing VJ, Tsukamoto K. Enzymatic control of pigmentation in mammals. FASEB J 1991; 5: 2902-2909.
10. Hearing VJ. Unravelling the melanocyte. Am J Hum Gen 1993; 52: 1-7.
11. Houghton AN. Cancer antigens: immune recognition of self and altered self. J Exp Med 1994; 180: 1-4.
12. Brichard V, Van Pel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993; 178: 489-495.
13. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994; 91: 6458-6462.
14. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180: 347-352.
15. Rosenberg SA. The immunotherapy of solid cancers based on cloning the genes encoding tumour-rejection antigens. Ann Rev Med 1996; 47: 481-491.
16. Dalgleish A. The case for therapeutic vaccines. Melanoma Res 1996; 6: 5-11.
17. Maeurer MJ, Storkus WJ, Kirkwood JM, Lotze MT. New treatment options tor patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res 1996; 6: 11-24.
18. Hearing VJ, Tsukamoto K, Urabe K, Kameyama K, Montague PM, Jackson IJ. Functional properties of cloned melanogenic proteins. In: Takeuchi T, Quevedo WCJ, eds. Molecular Biology of Pigment Cells, Copenhagen: Munksgaard, 1992: 264-270.
19. Kameyama K, Takemura T, Hamada Y, et al. Pigment production in murine melanoma cells is regulated by tyrosinase, tyrosinase-related protein 1 (TRP1), DOPAchrome tautomerase (TRP2) and a melanogenic inhibitor. J Invest Dermatol 1992; 100: 126-131.
20. Urabe K, Aroca P, Hearing VJ. From gene to protein: determination of melanin synthesis. Pigment Cell Res 1993; 6: 186-192.
21. Spritz RA, Hearing VJ. Genetic disorders of pigmentation. In: Hirschhorn K, Harris H, eds. Advances in Human Genetics. New York: Plenum Press, 1994: 1-45.
22. Kameyama K, Sakai C, Kuge S, et al. Expression of tyrosinase, tyrosinase-related proteins 1 and 2 (TRP1 and TRP2). silver protein and a melanogenic inhibitor regulates melanogenesis in human melanoma cells. Pigment Cell Res 1995; 8: 97-104.
23. Hearing VJ. The regulation of melanin formation. In: Nordlund JJ, Boissy RE, Hearing VJ, King RA, Ortonne JP, eds. The Pigment Cell: Its Physiology and Pathophysiology. New York: Oxford University Press, 1996.
24. King RA, Hearing VJ, Oetting WS. Abnormalities of pigmentation. In: Rimoin DL, Connor JM, Pyeritz RE, Emery AEH, eds. Emery and Rimoin's' Principles and Practice of Medical Genetics. New York: Churchill Livingston 1996; 1171-1203.
25. Boissy RE, Zhao H, Oetting WS, et al. Mutation in and lack of expression of tyrosinase related protein I (TRP1) in melanocytes from an individual with brown oculocutaneous albinism: a new subtype of albinism classified as OCA3. Am J Hum Gen 1996; 58: 1145-1156.
26. Bakker ABH, Schreurs MWJ, de Boer AJ, et al. Melanocyte-lineage specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994; 179: 1005-1009.
27. Lamoreux ML, Zhou BK, Rosemblat S, Orlow SJ. The melanogenic complex in pheomelanic mice. Pigment Cell Res 1994; 7: 28
28. Rosemblat S, Durham-Pierre D, Gardner JM, Nakatsu Y, Brilliant MH, Orlow SJ. Identification of a melanosomal membrane protein encoded by the pink-eyed dilution (type II oculocutaneous albinism) gene. Proc Natl Acad Sci USA 1994; 91: 12071-12075.
29. Lamoreux ML, Zhou BK, Rosemblat S, Orlow SJ. The pinkeyed-dilution protein and the eumelanin/pheomelanin switch: in support of a unifying hypothesis. Pigment Cell Res 1995; 8: 263-270.
30. Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994; 180: 35-42.
31. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994; 91: 3515-3519.
32. Kawakami Y, Battles JK, Kobayashi T, et al. Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1. J Immunol Methods 1996; (in press).
33. Klingler WG, Montague PM, Cretien PM, Hearing VJ. Atypical melanosomal proteins in human malignant melanoma. Arch Dermatol 1977; 113: 19-23.
34. Kerney SE, Montague PM, Cretien PM, Nicholson JM, Ekel TM, Hearing VJ. Intracellular localization of tumor-associated antigens in murine and human malignant melanoma. Cancer Res 1977; 37: 1519-1524.
35. Gersten DM, Hearing VJ, Marchalonis JJ. Characterization of immunologically significant unique B-16 melanoma proteins produced in vivo and in vitro. Proc Natl Acad Sci USA 1981; 78: 5109-5112.
36. Hearing VJ, Vieira W, Law LW. Malignant melanoma: cross-reacting (common) tumor rejection antigens. Int J Cancer 1985; 35: 403-409.
37. Hearing VJ, Gersten DM, Montague PM, Vieira WD, Galetto G, Law LW. Murine melanoma specific tumor rejection activity elicited by a purified, melanoma associated antigen. J Immunol 1986; 137: 379-384.
38. Law LW, Vieira WD, Kameyama K, Hearing VJ. A 'unique' tumor-rejection antigen (TSTA) from the S91 murine malignant melanoma. Cancer Res 1987; 47: 5841-5845.
39. Albino AP, Lloyd KO, Houghton AN, Oettgen HF, Old LJ. Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. J Exp Med 1981; 154: 1764-1778.
40. Houghton AN, Real FX, Davis LJ, Cordon-Cordo C, Old LJ. Phenotypic heterogeneity of melanoma: relation to the differentiation program of melanoma cells. J Exp Med 1987; 164: 812-829.
41. Kameyama K, Vieira WD, Tsukamoto K, Law LW, Hearing VJ. Differentiation and the tumorigenic and metastatic phenotype of murine melanoma cells. Int J Cancer 1990; 46: 1151-1158.
42. Tsukamoto K, Gersten DM, Law LW, Hearing VJ. Malignant melanoma: relationship to parameters of differentiation. Melanoma Res 1991; 1: 223-230.
43. b gene on expression of melanoma-associated antigen and lectin-binding sites on BL6 melanoma cells. Cancer Res 1991; 51: 5212-5218.
44. Ha oncogene. In: Mishima Y, ed. The Pigment Cell: From the Molecular to the Clinical Level, Copenhagen: Munksgaard, 1992; 181-184.
45. Prezioso JA, Hearing VJ, Muller J, Urabe K, Wang N, Gorelik E. Impairment of the melanogenic pathway in B16 melanoma cells transfected with class 1 H-2 genes. Melanoma Res 1995; 5: 15-26.
46. Bradl M, Klein-Szanto A, Porter S, Mintz B. Malignant melanoma in transgenic mice. Proc Natl Acad Sci USA 1991; 88: 164-168.
47. Larue L, Dougherty N, Mintz B. Genetic predisposition of transgenic mouse melanocytes to melanoma results in malignant melanoma after exposure to a low ultraviolet B intensity nontumorigenic for normal melanocytes. Proc Natl Acad Sci USA 1992; 89: 9534-9538.
48. Larue L, Dougherty N, Bradl M, Mintz B. Melanocyte culture lines from Tyr-SV40E transgenic mice: models for the molecular genetic evolution of malignant melanoma. Oncogene 1993; 8: 523-531.
49. Mintz B, Silvers WK. Transgenic mouse model of malignant skin melanoma. Proc Natl Acad Sci USA 1993; 90: 8817-8821.
50. Orlow SJ, Hearing VJ, Sakai C, et al. Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progression. Proc Natl Acad Sci USA 1995; 92: 10152-10156.
51. Gersten DM, Williams LJ, Moody D, Montague PM, Law LW, Hearing VJ. The intracellular association of B700 and B50 murine melanoma antigens and their role in tumor rejection. Int J Cancer 1989; 43: 497-500.
52. Shrayer D, Gersten DM, Koness J, Maizel A, Wanebo H, Hearing VJ. B700 antigen as a component of an antimelanoma vaccine: formalinized extracellular antigens. Pigment Cell Res 1992; 5: 107-112.
53. Shrayer D, Kouttab N, Maizel A, Wanebo H, Hearing VJ, Gersten DM. Generation of cytotoxic antibodies to the B16 murine melanoma using a formalinized vaccine. Int J Cancer 1993; 53: 696-702.
54. Gersten DM, Moody D, Vieira WD, Law LW, Hearing VJ. Production of monoclonal antibodies against the B700 murine melanoma antigen and their anti-metastatic properties. Biochim Biophys Acta 1992; 1138: 109-114.
55. Law LW, Vieira WD, Gersten DM, Hearing VJ. Further studies on the therapeutic effects of murine melanoma-specific monoclonal antibodies. Biochim Biophys Acta 1994; 1226: 105-109.
56. Hara I, Takechi Y, Houghton AN. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med 1995; 182: 1609-1614.
57. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 1988; 319: 1676-1680.
58. Rosenberg SA. Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1995; 86: 1159-1166.
59. Rubin JT, Elwood LJ, Rosenberg SA, et al. Immunohistochemical correlates of response to recombinant interleukin-2 based immunotherapy in humans. Cancer Res 1989; 49: 7086-7092.
60. Pockaj BA, Sherry R, Wei J, et al. Localization of indium-111 labelled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy: augmentation with cyclophosphamide in association with response. Cancer 1994; 73: 1731-1737.
61. Robbins PF, El-Gamil M, Kawakami Y, Rosenberg SA. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res 1994; 54: 3124-3126.
62. Wang RF, Robbins PF, Kawakami Y, Rang XQ, Rosenberg SA. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31 restricted tumor-infiltrating lymphocytes. J Exp Med 1995; 181: 799-804.
63. Kawakami Y, Eliyahu S, Jennings C, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995; 154: 3961-3968.
64. Bouchard B, Fuller BB, Vijayasaradhi S, Houghton AN. Induction of pigmentation in mouse fibroblasts by expression of human tyrosinase cDNA. J Exp Med 1989; 169: 2029-2042.
65. Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother 1996; 19: 81-84.
66. Wolfel T, Van Pel A, Brichard V, et al. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 1994; 24: 759-764.
67. Brichard V, Herman J, Van Pel A, et al. A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Eur J Immunol 1996; 26: 224-230.
68. Kang X, Kawakami Y, El-Gamil M, et al. Identification of a tyrosinase epitope recognized by HLA A24-restricted, tumor-infiltrating lymphocytes. J Immunol 1995; 155: 1343-1348.
69. Topalian SL, Rivoltini L, Mancini M, et al. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 1994; 91: 9461-9465.
70. Topalian SL, Gonzales MI, Parkhurst MR, et al. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med 1996; 183: 1965-1971.
71. Sensi M, Traversari C, Radrizzani M, et al. Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A MART-1. Proc Natl Acad Sci USA 1995; 92: 5674-5678.
72. Castelli C, Storkus WJ, Maeurer MJ, et al. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med 1995; 181: 363-368.
73. Cox AL, Skipper J, Chen Y, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994; 264: 716-719.
74. Dean AD, Frost-Mason SK. Effects of melanocyte-stimulating hormone on wild-type and white axolotl neural crest cells. Biochem Biophys Res Commun 1995; 210: 239-245.
75. Wang RF, Parkhurst MR, Kawakami Y, Robbins PF, Rosenherg SA. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J Exp Med 1996; 183: 1131-1140.
76. Falk K, Rotzschke O, Stevanovic S, et al. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1993; 351: 290-296.
77. Ruppert J, Sidney J, Celis ME, et al. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993; 74: 929-937.
78. Kast WM, Brandt RMP, Sidney J, et al. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol 1994; 152: 3904-3912.
79. Rivoltini L, Kawakami Y, Sakaguchi K, et al. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995; 154: 2257-2265.
80. Kawakami Y, Robbins PF, Wang RF, et al. Identification of tumor regression antigens in melanoma. In: DeVita VT, Hellman S, Rosenberg SA, eds. Important Advances in Oncology. Philadelphia: Lippincott-Raven, 1996: 3-21.
81. Kawakami Y, Rosenberg SA. T-cell recognition of self peptides as tumor rejection antigens. Immunol Res 1996; 15: 179-190.
82. Kawakami Y, Rosenberg SA. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. Int Rev Immunol 1997; (in press).
83. Kawakami Y, Zakut R, Topalian SL, Stotter H, Rosenberg SA. Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J Immunol 1992; 148: 638-643.
84. O'Neil HH, Kawakami Y, Restifo NP, et al. Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA. J Immunol 1993; 1410: 1418-1423.
85. Zhai Y, Yang JC, Kawakami Y, et al. Antigen-specific tumor vaccines: development and characterization of recombinant adenoviruses encoding MART-1 or gp100 for cancer therapy. J Immunol 1996; 156: 700-710.
86. Chamberlain RS, Carroll MW, Bronte V, et al. Costimulation enhances the active immunotherapy effect of recombinant anti-cancer vaccines. Cancer Res 1996; 56: 2832-2836.
87. Irvine K, Rao J, Rosenberg SA, et al. Cytokine enhancement of DNA immunization leads to treatment of established pulmonary metastases. J Immunol 1995; 156: 238-245.
88. Minev B, McFarland BJ, Spiess PJ, et al. Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolong survival of thymoma-bearing mice. Cancer Res 1994; 54: 4155-4161.
89. Udono H, Srivastava PK. Comparison of tumor specific immunogenicities of stress-induced proteins gp96, Hsp90 and Hsp80. J Immunol 1994; 152: 5398-5403.
90. Jager E, Ringhoffer M, Karbach J, Arand M, Oesch F, Knuth A. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic T-cell responses: evidence for immunoselections of antigen-loss variants in vivo. Int J Cancer 1996; 66: 470-476.
91. Chen W, Khilko S, Fecondo J, et al. Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues. J Exp Med 1994; 180: 1471-1483.
92. Parkhurst MR, Salgaller M, Southwood S, et al. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A0201 binding residues. J Immunol 1996; 157: 2539-2548.
93. Bronte V, Tsung K, Rao JB, et al. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol 1995; 154: 5282-5292.
94. Noguchi Y, Richards FC, Chen YT, et al. Influence of interleukin 12 on p53 peptide vaccination against established MethA sarcoma. Proc Natl Acad Sci USA 1996; 92: 2219-2223.
95. Rao JH, Chamberlain RS, Bronte V, et al. IL12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B71 expression. J Immunol 1996; 156: 3357-3365.
96. Matzinger P. Tolerance, danger and the extended family. Annu Rev Immunol 1994; 12: 991-1045.
97. Salgaller ML, Afshar A, Marincola FM, Rivoltini L, Kawakami Y, Rosenberg SA. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res 1995; 55: 4972-4979.
98. Visseren MJW, van Elsas A, van der Voort EIH, et al. CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J Immunol 1995; 154: 3991-3998.
99. Bakker ABH, Marland G, de Boer AJ, et al. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res 1995; 55: 5330-5334.
100. Cole DJ, Weil DP, Shilyansky J, et al. Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen. Cancer Res 1995; 55: 748-752.
101. Cole DJ, Weil DP, Shamamian P, et al. Identification of MART-1 specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope. Cancer Res 1994; 54: 5265-5268.
102. Chan CC, Palestine AG, Nussenblatt RB. Sympathetic ophthalmia and Vogt-Koyanagi-Harada syndrome. In: Tasman W, Jaeger EA, eds. Duane's' Clinical Opthalmology, Philadelphia: J.B. Lippincott, 1989: 1-10.
103. Restifo NP, Kawakami Y, Marincola FM, et al. Molecular mechanisms used by tumors to escape immune recognition: immuno-genetherapy and the cell biology of major histocompatibility complex class I. J Immunother 1993; 14: 182-190.
104. Topalian SL, Kasid A, Rosenberg SA. Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes: possible mechanisms for immunotherapeutic failures. J Immunol 1990; 144: 4487-4495.
105. Lehmann F, Marchand M, Hainaut P, et al. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 1995; 25: 340-347.
106. Marincola FM, Shamamian P, Alexander RB, et al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol 1994; 153: 1225-1237.
107. Marincola FM, Shamamian P, Simonis TB, et al. Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines. J Immunother 1995; 16: 13-23.
108. Restifo NP, Marincola FM, Kawakami Y, et al. Loss of functional β2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 1996; 88: 100-108.
109. Restifo NP, Esquivel F, Kawakami Y, et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993; 177: 265-272.
110. Sanda MG, Restifo NP, Walsh JC, et al. Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 1995; 87: 280-285.
111. Skipper JCA, Hendrickson RC, Gulden PH, et al. An HLA-A2 restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 1996; 183: 527-534.
112. Anichini A, Mortarini R, Maccalli C, et al. Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J Immunol 1996; 156: 208-217.
113. Coulie PG, Lehmann F, Lethe B, et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 1995; 92: 7976-7980.
114. Wolfel T, Hauer M, Schneider J, et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995; 269: 1281-1284.
115. Robbins PF, El-Gamil M, Li YF, et al. A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996; 183: 1185-1192.
116. Protti MP, Imro MA, Manfredi AA, et al. Paniculate naturally processed peptides prime a cytotoxic response against human melanoma in vitro. Cancer Res 1996; 56: 1210-1213.
117. Jaeger F, Bernhard H, Romero P, et al. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 1996; 66: 162-169.
118. Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 1996; 56: 2479-2483.
119. Vijayasaradhi S, Bouchard B, Houghton AN. The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med 1990; 171: 1375-1380.
120. Brown JP, Woodbury RG, Hart CE, Hellström I, Hellström KE. Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues. Proc Natl Acad Sci USA 1981; 78: 539-543.
121. Cui J, Harning R, Henn M, Bystryn JC. Identification of pigment cell antigens defined by vitiligo antibodies. J Invest Dermatol 1992; 98: 162-165.
122. Song YH, Connor E, Li Y, Zorovich B, Balducci P, Maclaren N. The role of tyrosinase in autoimmune vitiligo. Lancet 1994; 344: 1049-1052.
123. Austin LM, Boissy RE. Mammalian tyrosinase-related protein-1 is recognized by autoantibodies from vitiliginous Smyth chickens. Am J Pathol 1995; 146: 1529-1541.
124. Cui J, Arita Y, Bystryn JC. Characterization of vitiligo antigens. Pigment Cell Res 1995; 8: 53-59.
125. Tobin DJ, Orentreich N, Fenton DA, Bystryn JC. Antibodies to hair follicles in alopecia areata. J Invest Dermatol 1994; 102: 721-724.
126. Paus R, Slominski A, Czarnetzki BM. Is alopecia areata an autoimmune-response against melanogenesis-related proteins, exposed by abnormal MHC Class I expression in the anagen hair bulb? Yale J Biol Med 1994; 66: 541-554.
127. Sugita S, Sagawa K, Mochizuki M, Shichijo S, Itoh K. Melanocyte lysis by cytotoxic T lymphocytes recognizing the MART-1 melanoma antigen in HLA-A2 patients with Vogt-Koyanagi-Harada disease. Int Immunol 1996; 8: 799-803.
128. Kwon BS, Halaban R, Ponnazhagan S, et al. Mouse silver mutation is caused by a single base insertion in the putative cytoplasmic domain of Pmel 17. Nucl Acids Res 1995; 23: 154-158.
129. Zhai Y, Yang JC, Spiess P, et al. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J Immunother 1997; 20: 15-25.
130. Kang XQ, Robbins PF, Fitzgerald EB, et al. Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope major histocompatability complex class I fusion proteins. Cancer Res 1997; 57: 202-205.